CliniGA CRO

CliniGA CRO Blog

Maintaining trial continuity through sponsor corporate changes

A merger or business transfer can change who makes trial decisions and purchases services.

Representative research photograph: Maintaining trial continuity through sponsor corporate changes
Photo: U.S. Marine Corps photo by Staff Sgt. Sean Potter · License: Public domain · Cropped and resized.
Published
Updated

A merger or business transfer can change who makes trial decisions and purchases services. A corporate announcement does not automatically update study documents or external system records. Sponsor transition should explicitly connect the legal position with its practical implementation across ongoing trial activities.

Decision framework

Distinguish a change of legal entity, a trading-name change and an internal organisational change first. Regulatory, legal, safety and finance owners should identify affected obligations. External notification needs depend on the country and the nature of the change; this example does not provide a universal transfer procedure for every setting.

Worked example

For example, invoices will move to a new company after an acquisition, but the safety contact address has not been included in the plan. The team does not equate the financial update with completed transition. It also reviews investigator communications, authorised decisions and system accounts so that an open notification or event cannot fall between two organisations.

Implementation checks

  • Map changed identity and contact information to the relevant trial records and external systems that may be affected.
  • Record how responsibility will be determined for events occurring before and after the agreed transition point.
  • Check that instructions to providers and sites match the transition scope confirmed by authorised legal owners.

Acceptance and boundaries

Accept the transition when teams can describe one current, coherent allocation of responsibility. Commercial completion dates may differ from country-specific notification and implementation steps. Do not overlook gaps in participant protection, data access or record continuity because a corporate timetable has been met.

Frequently asked questions

Does a company-name change automatically update every authorisation?
No. Specialists should assess consequences and necessary actions for the applicable country and trial.
Can both companies work during a transition?
A suitable transition may be planned with explicit authority limits, communications and records.

Sources

  1. EMA — ICH E6 good clinical practice
  2. European Commission — Clinical trials framework